Artificial Heart Bridges Patient to New Life in UCSF Milestone

SAN FRANCISCO, CA – February 12, 2026 – By Tyler Nguyen

A 37-year-old patient from California’s Central Valley is recovering well today after a landmark procedure at UCSF Health, receiving a life-saving heart transplant that was made possible only after being sustained for months by a total artificial heart. The case represents a major clinical milestone for both the top-ranked hospital and for Picard Medical, Inc., the parent company of the device's manufacturer, SynCardia.

The patient was admitted to UCSF in August 2025 with end-stage biventricular heart failure, a devastating condition where both chambers of the heart can no longer pump blood effectively. Within weeks, a surgical team led by Dr. Amy Fiedler and Dr. Jason W. Smith implanted the SynCardia Total Artificial Heart (STAH), completely replacing the patient's failing organ. After being discharged with the device, the patient was able to wait for a matching donor. Three months later, that wait ended, and the patient successfully underwent transplantation, looking forward to returning home to a young daughter with renewed health.

This successful outcome is not just a personal victory but a powerful demonstration of the STAH's role as a 'bridge-to-transplant'—a mechanical solution that keeps the sickest patients alive and stable until a precious donor organ becomes available.

A Lifeline for the Failing Heart

For patients in the gravest stages of heart failure, time is the enemy. End-stage biventricular failure leaves patients critically ill, with multi-organ systems often beginning to shut down. While Left Ventricular Assist Devices (LVADs) can support a single failing ventricle, they are insufficient when the entire heart has given out. This is where a total artificial heart becomes the only viable option.

The SynCardia device is the only TAH commercially available in the United States and Canada, having been implanted over 2,100 times worldwide. It functions by completely removing the patient's diseased ventricles and replacing them with two new artificial ventricles and four valves, which are powered by an external pneumatic driver. This intervention immediately restores blood flow, reversing the damage to other vital organs and making the patient a healthier, more viable candidate for an eventual transplant.

Clinical data underscores the device's effectiveness in this critical role. While outcomes vary, studies have shown that over 60% of patients receiving the STAH are successfully bridged to transplantation. The average duration of support is around 130 days, though some patients have been sustained for several years. For the UCSF patient, the device provided the three-month window needed to find a compatible donor heart, transforming a near-certain fatality into a second chance at life.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical Inc., commented on the significance of the case in a press release. “This fifth case at UCSF highlights the continued clinical adoption of the SynCardia Total Artificial Heart at leading transplant centers and now has a corresponding successful heart transplantation. For patients in advanced biventricular failure, time is critical. The ability to stabilize and sustain these patients, so that they are also healthy enough for surgery until a suitable donor heart becomes available is central to our mission.”

A Landmark Collaboration in Cardiac Care

The success of this case is also a testament to the expertise at UCSF Health. The institution, which tied for the #1 hospital ranking in California by U.S. News & World Report for 2025-2026, runs one of the largest and most rapidly growing heart transplant programs in the nation. After performing just 17 heart transplants in 2020, the program conducted nearly 80 in 2023, a testament to its expanding capabilities.

UCSF is at the forefront of cardiac innovation, utilizing advanced organ preservation systems and performing complex procedures like transplants from donors after circulatory death (DCD), a practice still limited to a small number of U.S. health systems. This was the fifth time UCSF surgeons had implanted the SynCardia device, but the first of those patients to successfully proceed to transplant, marking a crucial validation of their TAH program, which was formally anticipated to begin in spring 2024.

The procedures, performed at the Helen Diller Medical Center at Parnassus Heights by Dr. Fiedler, Surgical Director of the Heart Transplant Program, and Dr. Smith, Chief of Cardiac Surgery, showcase the high level of skill required for such an intervention. As Northern California's only active program that fully implants the mechanical heart, UCSF is solidifying its position as a regional leader in advanced cardiac failure treatment.

The State of Artificial Heart Technology

While the SynCardia TAH is a life-saving marvel, it represents a technology that is still evolving. Cardiothoracic surgeons note that while the device is indispensable for a specific patient population, it is not without significant challenges. The most pressing issues are tied to its design: the external pneumatic driver requires percutaneous drivelines that breach the skin, creating a constant risk of infection. Indeed, infection and device malfunction are the most frequently reported adverse events, followed by bleeding and neurological complications.

Furthermore, the device's size can preclude its use in smaller adults and adolescents, and the noise and tethered nature of the external driver significantly impact a patient's quality of life. These limitations have fueled a competitive race to develop the next generation of artificial hearts.

French company Carmat is making headway with its Aeson® artificial heart, which uses biological materials to improve blood compatibility and has earned a CE mark in Europe. Meanwhile, BiVACOR is developing a highly advanced TAH using magnetic levitation technology, with its first human study beginning in 2024. These competitors are all chasing the same goal: a smaller, more durable, and fully implantable device.

The Next Frontier: Fully Implantable Hearts and Market Realities

Picard Medical is not standing still. The company is channeling its resources into the development of the Emperor TAH, its answer to the challenges of the current generation. The Emperor is designed to be a fully implantable system, eliminating the external drivelines and driver that are the primary source of complications and quality-of-life compromises with the existing SynCardia device. Successful preclinical implantations in late 2025 demonstrated stable circulation, signaling a major step toward a future where an artificial heart is not just a temporary bridge, but a long-term solution.

This innovation is critical for Picard Medical's future. The company, which went public in August 2025, faces the harsh financial realities of the medical device industry. Despite growing revenue from its STAH platform, the company has reported recurring net losses as it invests heavily in research and development. Its stock (NYSE American: PMI) has been volatile, reflecting both the immense promise of its technology and the high-risk nature of its business.

The journey of the UCSF patient perfectly encapsulates this dual reality. It is a story of a life saved by today's incredible, if imperfect, technology. Simultaneously, it highlights the urgent need for the next wave of innovation being pursued by Picard and its competitors—a future where a failing heart can be replaced not with a temporary bridge, but with a permanent, seamless, and silent machine that restores life from within.